Summit Therapeutics (SMMT) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Stifel Reiterates Hold Rating on Summit Therapeutics plc (SMMT)
February 24, 2025 1:40 PM ESTStifel analyst Brad Canino reiterated a Hold rating and $40.00 price target on Summit Therapeutics plc (NASDAQ: SMMT)
The analyst comments "Todays volatility is likely recent M&A conjecture falling out after management canceled three 1Q bank conferences, and less of a... More
